Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Accounts Payables (2021 - 2026)

Nuvectis Pharma has reported Accounts Payables over the past 6 years, most recently at $4.7 million for Q1 2026.

  • Quarterly results put Accounts Payables at $4.7 million for Q1 2026, up 56.92% from a year ago — trailing twelve months through Mar 2026 was $4.7 million (up 56.92% YoY), and the annual figure for FY2025 was $6.3 million, up 151.16%.
  • Accounts Payables reached $4.7 million in Q1 2026 per NVCT's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $6.4 million in Q3 2025 and bottomed at $1.3 million in Q1 2022.
  • Median Accounts Payables over the past 5 years was $2.5 million (2024), compared with a mean of $3.0 million.
  • The largest annual shift saw Accounts Payables plummeted 35.25% in 2024 before it soared 184.79% in 2025.
  • Over 5 years, Accounts Payables stood at $2.9 million in 2022, then dropped by 4.78% to $2.8 million in 2023, then fell by 9.85% to $2.5 million in 2024, then surged by 151.16% to $6.3 million in 2025, then fell by 25.17% to $4.7 million in 2026.
  • Business Quant data shows Accounts Payables for NVCT at $4.7 million in Q1 2026, $6.3 million in Q4 2025, and $6.4 million in Q3 2025.